Empasiprubart
-
argenx to Present Key Data and Immunology Advancements at AANEM & MGFA 2025
Argenx will present over 40 abstracts at the 2025 AANEM/MGFA meeting, highlighting data on VYVGART (IV and SC) and empasiprubart. Key presentations include ADAPT SERON results showing VYVGART’s efficacy in AChR antibody-negative gMG, interim ADAPT Jr data in juvenile gMG, and Phase 2/3 empasiprubart programs for CIDP and MMN (EMVIGORATE, EMNERGIZE, EMPASSION). Real-world evidence and long-term data will also be presented, reinforcing VYVGART’s sustained benefit. The conference will address concerns of allergic risks and infection management.
